VASOCIDIN
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Aug 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VASOCIDIN is an ophthalmic solution approved in 1988 for eye conditions, delivered as topical drops. The exact mechanism of action and indications are not publicly detailed in available data, limiting characterization of its therapeutic role.
LOE Approaching
Product is in LOE-approaching phase with moderate competitive pressure (30), suggesting contracted team resources and focus on lifecycle extension or generic transition support.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VASOCIDIN currently has zero linked job opportunities, reflecting its mature lifecycle status and small team footprint at Novartis. Career growth on this asset is limited; roles focus on lifecycle management, generic transition planning, and market defense rather than expansion.
Brand ManagerField Sales Representative
Worked on VASOCIDIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.